Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer
Tetsuo Tani(Keio University), Kenzo Soejima(Keio University), Hidefumi Koh(Tachikawa Hospital), Keita Masuzawa(Kitasato Institute Hospital), Shinnosuke Ikemura(Keio University), Keiko Ohgino(Keio University), Aoi Kuroda(Keio University), Hideki Terai(Kitasato Institute Hospital), Kota Ishioka(Keio University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Taro Shinozaki(Keio University), Koichi Fukunaga(Keio University), Yohei Funatsu(Keio University), Shigenari Nukaga(Tokyo Medical Center)
Cited by 7
Related Papers
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101